Cadonilimab with chemotherapy for stomach cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy before surgery for stomach or gastroesophageal junction cancer. The goal is to shrink the tumor and improve outcomes for patients who are candidates for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach or gastroesophageal junction cancer that can be removed by surgery (specific size and lymph node involvement)
- Your cancer cells are HER2-negative (a protein marker test shows 0, 1+, or non-amplified 2+)
- You have not received any prior chemotherapy, radiation, or immunotherapy for this cancer
- Your blood counts and organ function (liver, kidney, heart) are adequate to tolerate the study drugs
- You are willing to have tumor biopsies (small tissue samples) taken before and during treatment
- You are age 18 or older and in good enough health (ECOG performance 0 or 1) to receive the treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of an immunotherapy drug (cadonilimab) with chemotherapy before surgery for stomach cancer. The goal is to see if this approach shrinks tumors more effectively and improves outcomes.
This trial tests a combination of two drugs—nab-paclitaxel (a chemotherapy drug) and cadonilimab (an immunotherapy drug)—for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this combination can help shrink or control the cancer when other treatments haven't been tried yet.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests whether adding an immunotherapy drug (adebrelimab) and a targeted therapy (apatinib) to standard chemotherapy helps shrink stomach cancer before surgery. It aims to improve outcomes for people with advanced stomach cancer that cannot be removed or has spread.
This trial tests a new combination of immunotherapy (cadonilimab) and chemotherapy before and after surgery for a specific type of advanced stomach or gastroesophageal junction cancer. It aims to see if adding this immunotherapy helps shrink tumors and improve outcomes.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.